Evidence map›Paper›PMID 42537648›Full record

ArticleCell reports. Medicine2026

Early-life immune imprinting by a B. infantis-HMO synbiotic shapes infant immune signatures and protects against experimental respiratory disease.

Ridwan B Rashid, Cheong Kwong Chung, Patricia Namubiru, Tufael Ahmed, CLARA Study Group, Daniel R Howard, Ismail Sebina, Tyler Wilkins, Md Sohel Rana, Joshua P Morrow and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ridwan B RashidQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
Cheong Kwong ChungSociété des Produits Nestlé S.A., Nestlé Research, Nestlé Institute of Health Sciences, 1000 Lausanne, Switzerland.
Patricia NamubiruQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
Tufael AhmedQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
CLARA Study Group
Daniel R HowardQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
Ismail SebinaQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Tyler WilkinsQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
Md Sohel RanaQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
Joshua P MorrowMonash Instit4ute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.
Darren J CreekMonash Instit4ute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia.
Janne Marie MollCmbio, 2100 Copenhagen, Denmark.
Karine VidalSociété des Produits Nestlé S.A., Nestlé Research, Nestlé Institute of Health Sciences, 1000 Lausanne, Switzerland.
Cecilia FumeroSociété des Produits Nestlé S.A., Nestlé Research, Clinical Research Unit, 1000 Lausanne, Switzerland.
Luca LavalleSociété des Produits Nestlé S.A., Nestlé Research, Clinical Research Unit, 1000 Lausanne, Switzerland.
Dominick MaesSociété des Produits Nestlé S.A., Nestlé Product Technology Centre - Nutrition, 3510 Konolfingen, Switzerland.
Nicholas P HaysSociété des Produits Nestlé S.A., Nestlé Product Technology Center - Nutrition, 1800 Vevey, Switzerland.
Irma Silva-ZolezziSociété des Produits Nestlé S.A., Nestlé Product Technology Center - Nutrition, 1800 Vevey, Switzerland.
Elizabeth Forbes-BlomSociété des Produits Nestlé S.A., Nestlé Product Technology Center - Nutrition, 1800 Vevey, Switzerland.
Norbert SprengerSociété des Produits Nestlé S.A., Nestlé Research, Nestlé Institute of Health Sciences, 1000 Lausanne, Switzerland.
Jean-Charles PicaudDepartment of Neonatology, Hôpital de La Croix-Rousse, 69004 Lyon, France and CarMen Laboratory, INSERM, INRA, Université Claude Bernard Lyon 1, Pierre‑Bénite, 69310 Lyon, France.
Simon PhippsQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia; School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia. Electronic address: simon.phipps@qimbr.edu.au.
Mario NotiSociété des Produits Nestlé S.A., Nestlé Research, Nestlé Institute of Health Sciences, 1000 Lausanne, Switzerland. Electronic address: mario.noti@rd.nestle.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early microbial colonization influences immune development, with lower abundance of human milk oligosaccharide (HMO)-utilizing bifidobacteria linked to immune-related disorder risk. Here, we demonstrate that synbiotic supplementation with Bifidobacterium infantis (LMG 11588) and a blend of six structurally diverse HMOs plus Bifidobacterium lactis (CNCM I-3446) altered gut microbiome composition, changed systemic immune cell-networks, and reduced persistence of a T helper 2 (Th2) bias in formula-fed infants, following a pattern observed in breastfed infants. In preclinical models, synbiotic reduces lower respiratory tract infection (LRI) severity and aberrant type-2 immune responses and confers lasting immune benefits into adulthood. These effects are associated with changes in the circulating metabolome, including increased 12(S)-hydroxyheptadecatrienoic acid (12-HHT), which correlates with improved infection outcomes and phenocopies synbiotic-mediated protection when administered orally. Together, these findings indicate that infant-type synbiotic supplementation during a critical early-life window can imprint immune function and promote disease tolerance.

Indexed as

Bifidobacterium longum subspecies infantisMilk, HumanOligosaccharidesRespiratory Tract InfectionsSynbioticsAnimalsFemaleGastrointestinal MicrobiomeHumansInfantInfant, NewbornMaleTh2 CellsOligosaccharidesasthmaB. infantisbreastfeedingbronchiolitisHMOsimmune imprintinginfant-type bifidobacteriamicrobiome-host interactionsRSVsynbiotic

Identifiers

PMID42537648
PMCPMC13522788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.